Showing results (101-110 of 114) with videos related to

Sort By:
Pageof 12
Journal of Studies on Alcohol|January 1, 1993
A cross-study contextual analysis of effects from individual-level drinking and group-level drinking factors: a meta-analysis of multiple longitudinal studies from the collaborative alcohol-related longitudinal projectK M Fillmore, B M Johnstone, E V Leino, et al.
Health Care Financing Review|December 26, 2002
Use of conventional antipsychotics and the cost of treating schizophreniaR R Lyu, J S McCombs, B M Johnstone, et al.
Hearing Research|March 1, 1990
Saturation of outer hair cell receptor currents causes two-tone suppressionC D Geisler, G K Yates, R B Patuzzi, et al.
Journal of Studies on Alcohol|September 1, 1996
Determinants of life-course variation in the frequency of alcohol consumption: meta-analysis of studies from the collaborative alcohol-related longitudinal projectB M Johnstone, E V Leino, C R Ager, et al.
The Journal of the Acoustical Society of America|January 1, 1979
Cochlear action potential threshold and single unit thresholdsJ R Johnstone, V A Alder, B M Johnstone, et al.
Medical Care|April 27, 1999
Evaluation of antipsychotic and concomitant medication use patterns in patients with schizophreniaC L Williams, B M Johnstone, J G Kesterson, et al.
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research|February 9, 2006
Designing naturalistic prospective studies of economic and effectiveness outcomes associated with novel antipsychotic therapiesS L Tunis, B M Johnstone, B J Kinon, et al.
Pharmacoeconomics|March 3, 2001
Olanzapine versus risperidone. A prospective comparison of clinical and economic outcomes in schizophreniaE T Edgell, S W Andersen, B M Johnstone, et al.
Medical Care|July 29, 1999
Reliability, validity, and application of the medical outcomes study 36-item short-form health survey (SF-36) in schizophrenic patients treated with olanzapine versus haloperidolS L Tunis, T W Croghan, D K Heilman, et al.
The Journal of Clinical Psychiatry|October 3, 1999
Changes in perceived health and functioning as a cost-effectiveness measure for olanzapine versus haloperidol treatment of schizophreniaS L Tunis, B M Johnstone, P J Gibson, et al.
Pageof 12